Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 March;64(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 March;64(1):105-14

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 March;64(1):105-14

DOI: 10.23736/S1824-4785.18.03025-X

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Blood-brain barrier transport kinetics of NOTA-modified proteins: the somatropin case

Nathalie BRACKE 1, Yorick JANSSENS 1, Evelien WYNENDAELE 1, Liesa TACK 1, Alex MAES 2, 3, Christophe van de WIELE 4, Mike SATHEKGE 5, Bart de SPIEGELEER 1

1 Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium; 2 Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium; 3 Department of Nuclear Medicine, AZ Groeninge, Kortrijk, Belgium; 4 Department of Radiology and Nuclear Medicine, Ghent University, Ghent, Belgium; 5 Department of Nuclear Medicine, Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa



BACKGROUND: Chemical modifications such as PEG, polyamine and radiolabeling on proteins can alter their pharmacokinetic behavior and their blood-brain barrier (BBB) transport characteristics. NOTA, i.e. 1,4,7-triazacyclononane-1,4,7-triacetic acid, is a bifunctional chelating agent that has attracted the interest of the scientific community for its high complexation constant with metals like gallium. Until now, the comparative BBB transport characteristics of NOTA-modified proteins versus unmodified proteins are not yet described.
METHODS: Somatropin (i.e. recombinant human growth hormone), NOTA-conjugated somatropin and gallium-labelled NOTA-conjugated somatropin were investigated for their brain penetration characteristics (multiple time regression and capillary depletion [CD]) in an in vivo mice model to determine the blood-brain transfer properties.
RESULTS: The three compounds showed comparable initial brain influx, with Kin=0.38±0.14 µL/(g×min), 0.36±0.16 µL/(g×min) and 0.28±0.18 µL/(g×min), respectively. CD indicated that more than 80% of the influxed compounds reached the brain parenchyma. All three compounds were in vivo stable in serum and brain during the time frame of the experiments.
CONCLUSIONS: Our results show that modification of NOTA as well as gallium chelation onto proteins, in casu somatropin, does not lead to a significantly changed pharmacokinetic profile at the blood-brain barrier.


KEY WORDS: Blood-brain barrier; Permeability; Gallium; Chelation therapy; Growth hormone

inizio pagina